AI assistant
Centessa Pharmaceuticals plc — Director's Dealing 2024
Feb 2, 2024
31309_dirs_2024-02-02_f436eb50-4699-4921-acf7-fc5c1f61a839.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Centessa Pharmaceuticals plc (CNTA)
CIK: 0001847903
Period of Report: 2024-02-01
Reporting Person: Anderson Karen M. (Chief People Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-01 | Ordinary Shares | A | 31250 | — | Acquired | 84950 | Direct |
| 2024-02-01 | Ordinary Shares | F | 7265 | $8.19 | Disposed | 77685 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-01 | Share Option (right to buy) | $8.01 | A | 125000 | Acquired | 2034-02-01 | Ordinary Shares (125000) | Direct |
Footnotes
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 1, 2025.
F3: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
F4: 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2024.